Logistical Considerations of the Cell Therapy Supply Chain at the Point of Care

In by

Spotlight Article

Interview

Karen Coopman

SUPPLY CHAIN MANAGEMENT PART 2: CREATING A LOGISTICS STRATEGY FOR COMMERCIALIZATION

Karen Coopman has a background in pharmacology and has always had an interest in healthcare. The overarching theme of Karen’s research is the manufacture of cellular therapies. The ultimate aim is to generate a viable stem cell bioprocess such that clinically relevant cell numbers can be generated whilst ensuring product potency, purity and safety. Developing scalable systems for stem cell growth and improving methods of cell preservation are the current focus of her group. A Reader in Biological Engineering at Loughborough University, she is the Director of the EPSRC/MRC Centre for Doctoral Training in Regenerative Medicine and is also on the Steering Group of BioProNET and Chair of ESACT UK, the UK Society for Cell Culture Biotechnology.

DOI: 10.18609/cgti.2018.051
Citation: Cell Gene Therapy Insights 2018; 4(5), 501-508.
Open access

This content is restricted to registered users. Click here to Register or Login here.